Current and Emerging Inflammatory Biomarkers of Chronic Rhinosinusitis
- 1Unit of Otolaryngology, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
- 2Otolaryngology and Head and Neck Unit, ASL Bari, Bari, Italy
Abstract
Chronic rhinosinusitis, CRS, is a heterogeneous inflammatory disease of the sinonasal mucosa. Although the traditional distinction between chronic rhinosinusitis with nasal polyps, CRSwNP, and chronic rhinosinusitis without nasal polyps, CRSsNP, remains clinically useful, it does not fully reflect the biological complexity of the disease. Current biomarker approaches are often limited by incomplete correspondence between systemic markers and the local sinonasal inflammatory microenvironment, making integrated assessment increasingly relevant for endotyping, prognosis, therapeutic selection, and longitudinal monitoring. This narrative review summarizes established and emerging inflammatory biomarkers in CRS, with particular emphasis on CRSwNP. Established or clinically accessible biomarkers, including blood eosinophils, tissue eosinophilia, total IgE, FeNO, olfactory testing, endoscopic scores, radiological findings, and patient-reported outcomes, are discussed together with emerging or mainly translational biomarkers such as epithelial alarmins, Galectin-10, Charcot-Leyden crystals, extracellular traps, mucins, local IgE, mast cells, neutrophils, microbial biomarkers, biofilm-related patterns, and tissue remodeling mediators. No single biomarker appears sufficient to guide personalized management alone. An integrated framework combining molecular, cellular, epithelial, microbial, functional, radiological, endoscopic, and patient-reported data may provide a more accurate assessment of disease activity and therapeutic response. Within this framework, nasal cytology and Clinical-Cytological Grading, CCG, represent minimally invasive, repeatable, and practical tools that directly reflect local inflammation and may support endotypic stratification, recurrence risk assessment, treatment selection, and follow-up in severe and recurrent CRSwNP.
Related
- Oxidative Stress in Chronic Rhinosinusitis with Nasal Polyps: Pathophysiological Mechanisms, Biomarkers, and Therapeutic Implications
- Inflammatory Signatures Beyond Th1/Th2 Endotypes Provide Insights Into Postoperative Recurrence in Chronic Rhinosinusitis
- Chronic Occupational Stress and Immune–Inflammatory Dysregulation: Mechanisms, Clinical Consequences, Biomarkers and Implications for Occupational Medicine
- Pathophysiology and Emerging Therapies in Chronic Inflammatory Demyelinating Polyneuropathy
- Emerging Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current Evidence, Clinical Utility, and Future Perspectives.
BibTeX
@article{gelardi2026current,
title = {{Current and Emerging Inflammatory Biomarkers of Chronic Rhinosinusitis}},
author = {Matteo Gelardi and Rossana Giancaspro and Michele Cassano},
journal = {Journal of Inflammation Research},
year = {2026},
month = oct,
doi = {10.2147/jir.s546306},
url = {https://doi.org/10.2147/jir.s546306},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Current and Emerging Inflammatory Biomarkers of Chronic Rhinosinusitis
AU - Matteo Gelardi
AU - Rossana Giancaspro
AU - Michele Cassano
PY - 2026
DA - 2026/10/30
JO - Journal of Inflammation Research
DO - 10.2147/jir.s546306
UR - https://doi.org/10.2147/jir.s546306
AB - Chronic rhinosinusitis, CRS, is a heterogeneous inflammatory disease of the sinonasal mucosa. Although the traditional distinction between chronic rhinosinusitis with nasal polyps, CRSwNP, and chronic rhinosinusitis without nasal polyps, CRSsNP, remains clinically useful, it does not fully reflect the biological complexity of the disease. Current biomarker approaches are often limited by incomplete correspondence between systemic markers and the local sinonasal inflammatory microenvironment, making integrated assessment increasingly relevant for endotyping, prognosis, therapeutic selection, and longitudinal monitoring. This narrative review summarizes established and emerging inflammatory biomarkers in CRS, with particular emphasis on CRSwNP. Established or clinically accessible biomarkers, including blood eosinophils, tissue eosinophilia, total IgE, FeNO, olfactory testing, endoscopic scores, radiological findings, and patient-reported outcomes, are discussed together with emerging or mainly translational biomarkers such as epithelial alarmins, Galectin-10, Charcot-Leyden crystals, extracellular traps, mucins, local IgE, mast cells, neutrophils, microbial biomarkers, biofilm-related patterns, and tissue remodeling mediators. No single biomarker appears sufficient to guide personalized management alone. An integrated framework combining molecular, cellular, epithelial, microbial, functional, radiological, endoscopic, and patient-reported data may provide a more accurate assessment of disease activity and therapeutic response. Within this framework, nasal cytology and Clinical-Cytological Grading, CCG, represent minimally invasive, repeatable, and practical tools that directly reflect local inflammation and may support endotypic stratification, recurrence risk assessment, treatment selection, and follow-up in severe and recurrent CRSwNP.
SN - 1178-7031
ER -